The extension of the DEP-Docetaxel trial for another 3.5 years after this announcement certainly kept a few people employed for another few years.
Sad to know that Starpharma’s original and much hyped flagship drug is now shelved. The biggest travesty was that poor shareholders getting strung along with carrot dangling for years.
DEP-DUDextaxel
Ann: DEP docetaxel and gemcitabine combination trial commences, page-18
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.97M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 117445 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 121525 | 5 |
View Market Depth
| Last trade - 09.52am 05/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |
Day chart unavailable